DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process

7. Januar 2021 INDIZES USA

DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it has determined that it now qualifies as a U.
(Orginal – Story lesen…)

Tags: dow jones nasdaq s&p 500

You may also like...